Skip to main content

Biodesix Adds $12M to Series E Financing

NEW YORK (GenomeWeb) – Biodesix said today that it has added $12 million in follow-on financing to a series E round that raised $15 million in 2013 and 2014, bringing total proceeds of the sale to $27 million.

The company said that existing shareholders provided nearly all of the capital for the follow-on sale.

Biodesix will use the investment to continue development of its blood-based molecular diagnostic technology platform and test menu. It will also support the commercialization efforts of the company's VeriStrat serum protein test, which helps physicians select the appropriate therapy for patients with advanced non-small cell lung cancer.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.